Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | GUCY1B2 | O75343 | 4/20 | 0.35 |
| ▸ | GUCY1A2 | P33402 | 4/20 | 0.35 |
| ▸ | GUCY1A1 | Q02108 | 4/20 | 0.35 |
| ▸ | GUCY1B1 | Q02153 | 4/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18182083 | 0.91 | MRGPRX4 (0.40) | MRGPRX4MAPTNPSR1SLC22A12PTGER1 | |
| SCHEMBL18178948 | 0.88 | SLC22A12 (0.47) | MRGPRX4RAB9AMAPTNPSR1SLC22A12 | |
| SCHEMBL18178824 | 0.88 | MRGPRX4 (0.47) | MRGPRX4RAB9APTGER1PPARDFFAR4 | |
| SCHEMBL18178991 | 0.87 | MRGPRX4 (0.44) | MRGPRX4RAB9AMAPTNPSR1SLC22A12 | |
| SCHEMBL18178954 | 0.85 | MAPT (0.40) | MRGPRX4RAB9AMAPTNPSR1SLC22A12 | |
| SCHEMBL18178951 | 0.85 | MAPT (0.40) | MRGPRX4RAB9AMAPTNPSR1SLC22A12 | |
| SCHEMBL18178950 | 0.85 | MAPT (0.40) | MRGPRX4RAB9AMAPTNPSR1SLC22A12 | |
| SCHEMBL18178949 | 0.85 | MAPT (0.40) | MRGPRX4RAB9AMAPTNPSR1SLC22A12 | |
| SCHEMBL18178945 | 0.85 | MRGPRX4 (0.40) | MRGPRX4RAB9AMAPTNPSR1SLC22A12 | |
| SCHEMBL18178745 | 0.85 | MRGPRX4 (0.43) | MRGPRX4RAB9AMAPTNPSR1SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573904-B2 | Aromatic compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-21 | — | — | US | disclosed |
| US-20160311775-A1 | AROMATIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311775-A1 | AROMATIC COMPOUND AND USE THEREOF | ZCCHC8, CBR3, CBX8 | MRGPRX4 167/4885RAB9A 1136/4885MAPT 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.